The first calcitonin gene-related peptide (CGRP) inhibitor to be PBS listed will prompt reassessment for many patients severely affected by migraine, a leading neurologist says.

Associate Professor Richard Stark, from the Alfred Hospital in Melbourne, said the listing of galcanezumab (Emgality, Eli Lilly) from 1 June for patients with chronic migraine was a “tremendous milestone”.

“This … will prompt the reassessment of a large number of patients at the severe end of the migraine spectrum,” Professor Stark told Neurology Update.

“The importance of new forms of effective and well-tolerated migraine prevention cannot be overstated.”